Introduction: Pulmonary embolism is a diagnostic and therapeutic emergency that can be life-threatening. Its mortality is largely attributable to severe forms classically defined by clinical and morphological criteria. The aim of this study is to establish the role of two cardiac biomarkers (NT-proBNP and troponin) in assessing the severity of pulmonary embolism. Patients and Methods: We conducted a descriptive and analytical cross-sectional study. Data collection was retrospective over the period from January 1, 2011 to December 31, 2021. All patients hospitalized for pulmonary embolism in two cardiology referral clinics in Cotonou (Atinkanmey Polyclinic and CICA Clinic) were included. Results: The hospital prevalence of pulmonary embolism was 9.08%. The mean age was 52.6 years, with extremes of 18 and 92 years. The sex ratio was 0.73. Pulmonary embolism was severe according to hemodynamic, morphological and sPESI criteria in 12%, 24% and 39% of cases respectively, and mortality was 61.53%. Mean NT-ProBNP and troponin I levels were significantly higher in patients with severe criteria than in those without. NT-proBNP and troponin had good specificity for predicting cardiovascular arrest (99% and 90%), shock (100% and 98%), and hypotension (99% and 96%). NT-proBNP has the best positive predictive values in relation to the occurrence of shock (100%) and right ventricular dilatation (93%). The best correlation coefficient was obtained between right ventricular dilatation and NT-proBNP (0.78). Conclusion: NT-proBNP and troponin I are good biomarkers for predicting the severity of pulmonary embolism and allowing therapeutic adaptation when they are elevated.
References
[1]
Konstantinides, S.V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., et al. (2019) ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 54, Article ID: 1901647. https://doi.org/10.1183/13993003.01647-2019
[2]
Oloude, T. (2009) Gestion de l’embolie pulmonaire en cardiologie au CNHU-HKM de Cotonou du 1 septembre 2009 au 31 août 2014. 59 p.
[3]
N’djessan, J.J., Soya, E., Monney, E., Kouame, J., Takogue, R. and Konin, C. (2018) Evaluation de la mortalité précoce de l’embolie pulmonaire à l’Unité des Soins Intensifs de l’Institut de Cardiologie d’Abidjan. Cardiologie Tropicale, 152, 44-55. https://tropical-cardiology.com/Accueil/index.php/fr/2013-08-10-06-44-55/annee-2018/n-152-avr-mai-juin-2018
[4]
Goldhaber, S.Z., Visani, L. and Rosa, M.D. (1999) Acute Pulmonary Embolism: Clinical Outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). The Lancet, 353, 1386-1389. https://doi.org/10.1016/S0140-6736(98)07534-5
[5]
Philippot, Q., Roche, A., Goyard, C., Pastré, J., Planquette, B., Belmont, L., et al. (2018) Prise en charge de l’embolie pulmonaire grave en réanimation. Médecine Intensive Réanimation, 27, 443-451. https://doi.org/10.3166/rea-2018-0037
[6]
Dores, H., Fonseca, C., Leal, S., Rosário, I., Abecasis, J., Monge, J., et al. (2011) NT-proBNP for Risk Stratification of Pulmonary Embolism. Revista Portuguesa de Cardiologia, 30, 881-886. https://doi.org/10.1016/j.repce.2011.11.007
[7]
Empana, J.P., Lerner, I., Perier, M.C., Guibout, C., Jabre, P., Bailly, K., et al. (2022) Ultrasensitive Troponin I and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, 1471-1481. https://doi.org/10.1161/ATVBAHA.122.317961
[8]
Bi, W., Liang, S., He, Z., Jin, Y., Lang, Z., Liu, H., et al. (2021) The Prognostic Value of the Serum Levels of Brain Natriuretic Peptide, Troponin I, and D-Dimer, In Addition to the Neutrophil-to-Lymphocyte Ratio, For the Disease Evaluation of Patients with Acute Pulmonary Embolism. International Journal of General Medicine, 14, 303-308. https://doi.org/10.2147/IJGM.S288975
[9]
Zimonse, A. (2019) Embolie pulmonaire: Aspects diagnostiques à la clinique universitaire de cardiologie. Mémoire de DES, FSS Cotonou, 66 p.
[10]
Maiga, A.K., Sonfo, B., Coumba, T.A., Daouda, F., Konate, M., Sanoussi, D., et al. (2021) Prévalence de l’Embolie Pulmonaire dans le Service de Cardiologie du CHU-ME “Le Luxembourg” de Bamako avant la Pandémie de SRAS-COVID 19. Health Sciences and Diseases, 22, 71-74.
[11]
Pessinaba, S., Atti, Y.D.M., Baragou, S., Yayehd, K., Pio, M., Afassinou, Y.M., et al. (2019) La thrombolyse dans l’embolie pulmonaire à haut risque de mortalité: Expérience d’un service de cardiologie d’Afrique Subsaharienne. Annales de Cardiologie et d’Angéiologie, 68, 28-31. https://doi.org/10.1016/j.ancard.2018.08.026
[12]
Babaka, K., Savadogo, S., Koutonin, E., Diagne-Sow, D., Kane, M., Diack, B. and Mbaye, A. (2016) Embolie pulmonaire à haut risque de décès précoce: à propos de 13 cas. Tropical-Cardiology, 143, 23-29. https://tropical-cardiology.com/Accueil/index.php/fr/2013-08-10-06-44-55/annee-2016/volume-n-143-livret-d-abstract?start=64
[13]
Dossou, G.D. (2019) Embolie pulmonaire à la clinique universitaire de cardiologie du CNHU-HKM de Cotonou: Mortalité et facteur associés. Mémoire de DES, FSS Cotonou, 69 p.
[14]
Lagoye, D.G. (2019) Etude de la prise en charge de l’embolie pulmonaire a la clinique universitaire de cardiologie du CNHU-HKM de Cotonou. Mémoire de DES, FSS Cotonou, 64 p.
Hall, C. (2005) NT-ProBNP: The Mechanism behind the Marker. Journal of Cardiac Failure, 11, S81-S83. https://doi.org/10.1016/j.cardfail.2005.04.019
[17]
Azarian, R., Wartski, M., Collignon, M.A., Parent, F., Herve, P., Sors, H., et al. (1997) Lung Perfusion Scans and Hemodynamics in Acute and Chronic Pulmonary Embolism. Journal of Nuclear Medicine, 38, 980-983.
[18]
Pruszczyk, P. (2005) N-Terminal Pro-Brain Natriuretic Peptide as an Indicator of Right Ventricular Dysfunction. Journal of Cardiac Failure, 11, S65-S69. https://doi.org/10.1016/j.cardfail.2005.04.016
[19]
Zannou, D.M., Agbodande, K.A., Azon-Kouanou, A., Baglo, D.P.T., Wanvoegbe, F.A., Eyisse, Y. and Mousse, L. (2015) Contribution of the Dosage of Nt-ProBNP in the Assessment of Pulmonary Embolism Severity in Black African Community. Internal Medicine, 5, Article ID: 1000185. https://doi.org/10.4172/2165-8048.1000185
[20]
Henzler, T., Roeger, S., Meyer, M., Schoepf, U.J., Nance, J.W., Haghi, D., et al. (2012) Pulmonary Embolism: CT Signs and Cardiac Biomarkers for Predicting Right Ventricular Dysfunction. European Respiratory Journal, 39, 919-926. https://doi.org/10.1183/09031936.00088711
[21]
Cavallazzi, R., Nair, A., Vasu, T. and Marik, P.E. (2008) Natriuretic Peptides in Acute Pulmonary Embolism: A Systematic Review. Intensive Care Medicine, 34, 2147-2156. https://doi.org/10.1007/s00134-008-1214-5
[22]
Alpert, J.S., Thygesen, K., Antman, E. and Bassand, J.P. (2000) Myocardial Infarction Redefined—A Consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Journal of the American College of Cardiology, 36, 959-969. https://doi.org/10.1016/S0735-1097(00)00804-4
[23]
Amorim, S., Dias, P., Rodrigues, R.A., Araujo, V., Macedo, F., Maciel, M.J., et al. (2006) Troponin I as a Marker of Right Ventricular Dysfunction and Severity of Pulmonary Embolism. Revista Portuguesa de Cardiologia, 25, 181-186.
[24]
Liu, F.F., Gong, J.N., Jiang, Y., Kuang, T.G. and Yang, Y.H. (2018) Diagnostic Value of Serum Cardiac Biomarkers for Right Ventricular Dysfunction in Non-High-Risk Patients with Acute Pulmonary Thromboembolism. Chinese Journal of Tuberculosis and Respiratory Diseases, 41, 847-852.
